Kevin Conroy

Chairman and CEO, Exact Sciences

Joined Exact Sciences: 2009

Kevin Conroy became CEO of Exact Sciences in 2009 and Chairman in 2014, transforming the organization into one of the world’s premier cancer diagnostics companies with more than 6,500 employees. Under his leadership, Exact Sciences is working to change the future of cancer care through innovative tests that help prevent cancer, detect it earlier and guide successful treatment.

Kevin led Exact Sciences through the development and commercialization of its noninvasive colorectal cancer screening test, Cologuard®, which became the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States. The company also provides the Oncotype DX® test, which has spared more than one million breast cancer patients from chemotherapy while helping to predict the risk of their cancer returning.

Kevin has overseen the acquisition of more than 10 companies, including Genomic Health, Thrive, PreventionGenetics, Ashion and Biomatrica, growing Exact Sciences and positioning it for future success. Building on its strong foundation, the company has a robust pipeline which includes tests for multi-cancer early detection and molecular residual disease.

Before joining Exact Sciences, Kevin served as CEO and President of Third Wave Technologies, held leadership positions at GE Healthcare and practiced intellectual property law in private practice.

Kevin serves on the board of the American Clinical Laboratory Association and Align Technology. He is active in the Wisconsin community, serving as a director of the Greater Madison Chamber of Commerce.

He has spoken at industry-leading events including the STAT Summit, HLTH and the Personalized Medicine Conference.

A native of Flint, Michigan, he holds a Bachelor of Science degree in electrical engineering from Michigan State University and earned his law degree from the University of Michigan Law School.

7Asset 1

“What excites me most about working at Exact Sciences? Solving hard problems with exceptional people. It’s incredibly energizing to know that our collective ability and experience are making a real difference in the early detection of cancer, a space in which few companies have been able to carve out a leadership position. I’m just as excited that we’re putting our skills and know-how to work bringing other products to market where we can make a similar difference.

The mission we’ve outlined and the challenges in front of us put Exact Sciences in a unique leadership position to help win the war on cancer through early detection."

Kevin Conroy Chief Executive Officer, President, and Chairman of the Board